

Botulinum Toxin Injection

abobotulinumtoxinA (Dysport®), incobotulinumtoxinA (Xeomin®), daxibotulinumtoxinA-lanm (Daxxify®) letibotulinumtoxinA-wlbg (Letybo®), onabotulinumtoxinA (Botox®), rimabotulinumtoxinB (Myobloc®) FOR ADMINISTRATION BY A HEALTHCARE PROFESSIONAL

PRIOR REVIEW/CERTIFICATION REQUEST FOR SERVICES FORM INCOMPLETE FORMS MAY DELAY PROCESSING ALL NC PROVIDERS MUST PROVIDE THEIR 5-DIGIT Blue Cross NC PROVIDER ID# BELOW

PATIENT NAME		BLUE CROSS NO	MEMBER ID NUMBER	PATIENT DATE OF BIRT	Н	
REQUESTING PROVID	ER INFORMATION		SERVICING PROVIDER OR FACILITY LOCATION			
				ormed outside of the physicia	n office)	
Provider Name			Servicing Provider			
Provider #, Tax ID # or NPI			Facility Name			
Street, Bldg., Suite #			Servicing provider or Facility # or NPI #			
City/State/Zip code			Street, Bldg., Suite #			
Phone #			City/State/Zip code			
Fax #						
PLACE OF SERVICE:	☐ Home Infusion ☐ Offi	ce □ Outpatient h	ospital Specialty Pha	-		
Specialty Pharmacy:			Specialty Pharmacy NF			
HCPCS CODE:			CPT/Other billing code			
Primary Diagnosis:			ICD-10:			
Drug Requested:						
Strength & Route of Ac						
	equested medication a continuation coverage	and answer the f	following questions f	or <u>INITIAL</u> coverage:		
☐ Botox – J05 ☐ Daxxify – J0	<i>,</i> ,	ort – J0586 loc – J0587	□ Letybo – C93 □ Xeomin – J0	899, J3490, J3590** 588		
1. Will the requeste	ed medication be used f	or cosmetic purp	oses (e.g., glabellar lir	es, wrinkles)?□ Yes	□ No	
2. Will the patient b	e receiving botulinum to	oxin more freque	ntly than every 12 wee	ks? □ Yes	□ No	
3. Does the patient	t have a diagnosis of bl e	epharospasm?		□ Yes	□ No	
-	answer the following q	•				
a. Is the pa	itient 12 years of age or	older?		□ Yes	□ No	
				□ Yes	□ No	
				□ Yes	□ No	
If YES, please answer the following questions:						
 Is the patient's blepharospasm associated with dystonia or facial nerve (VII) 						
disorders (including benign essential blepharospasm and hemifacial						
					□ No	
 Has the patient tried and had an inadequate response with Xeomin?□ Yes □ No If YES, medical record documentation required. 						
				erance to Xeomin? ☐ Yes	□ No	
	•		ntation required.			
*	***continued on page 2; please complete and sign page 6 for prior authorization request***					

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the priority of their respective owners.



4.	Does t	he patient have a diagnosis of hemifacial spasm ?□ Yes	□ No
5.	childbi	he patient have a diagnosis of cervical dystonia (spasmodic torticollis: congenital, due to rth injury, or traumatic injury)?	□ No
	If YES	, please answer the following questions:	
	a.		□ No
	b.	Is the patient's cervical dystonia associated with sustained head tilt or abnormal posturing	
		with limited range of motion in the neck?□ Yes	□ No
	C.	Does the patient have a history of recurrent involuntary contraction(s) of one or more of the	
		muscles of the neck (e.g., sternocleidomastoid, splenius, trapezius, or posterior cervical	
		muscles)? Yes	□ No
	d.	Is the request for Botox, Daxxify, or Myobloc?□ Yes	□ No
		If YES, please answer the following questions:	
		i. Has the patient tried and had an inadequate response with Xeomin?□ Yes	□ No
		If YES, medical record documentation is required.	
		ii. Has the patient tried and had an inadequate response with Dysport?□ Yes	□ No
		If YES, medical record documentation is required.	
		iii. Does the patient have a clinical contraindication or intolerance to BOTH Xeomin	
		AND Dysport?□ Yes	□ No
		If YES, medical record documentation is required.	
6.	Does t	he patient have a diagnosis of dystonia ?□ Yes	□ No
٥.		, please answer the following questions:	_ 110
		Is the patient 18 years of age or older?	□ No
		Does the patient have any of the following focal dystonias:	_ 140
	D.	i. Focal upper-limb dystonia (e.g., organic writer's cramp)?□ Yes	□ No
		ii. Oromandibular dystonia (e.g., orofacial dyskinesia, Meige syndrome)?	
		iii. Laryngeal dystonia (e.g., adductor spasmodic dysphonia)?	□ No
		iv. Idiopathic (primary or genetic) torsion dystonia?	□ No
		v. Symptomatic (acquired) torsion dystonia?	□ No
	C.	Does the patient's dystonia result in functional impairment (interference with joint function,	
	٥.	mobility, communication, nutritional intake) with or without pain?	□ No
	d.		□No
	e.	Is the request for Botox, Daxxify, or Myobloc?	□ No
	С.	If YES, please answer the following questions:	
		i. Has the patient tried and had an inadequate response with Xeomin?□ Yes	□ No
		If YES, medical record documentation is required.	□ Na
		ii. Has the patient tried and had an inadequate response with Dysport?	□ No
		If YES, medical record documentation is required.	
		iii. Does the patient have a clinical contraindication or intolerance to BOTH Xeomin	
		AND Dysport?	□ No
		If YES, medical record documentation is required.	

continued on page 3; please complete and sign page 6 for prior authorization request

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the priority of their respective owners.



7.	Does t	he patient have a diagnosis of spasticity ?	□ Yes	□ No
	If YES	, please answer the following questions:		
		Is the patient 2 years of age or older?	□ Yes	□ No
	b.	Does the patient have any of the following spastic conditions:		
		i. Upper and/or lower limb spasticity?	□ Yes	□ No
		ii. Cerebral palsy?		□ No
		iii. Spasticity related to stroke?		□ No
		iv. Acquired spinal cord or brain injury?		□ No
		v. Hereditary spastic paraparesis?		□ No
		vi. Spastic hemiplegia?		□No
		vii. Neuromyelitis optica?viii. Multiple sclerosis or Schilder's disease?		□ No □ No
		·		
	C.	Does the patient's spasticity result in functional impairment (interference with joint functional limbs and interference with joint functional limbs and int		
	الم	mobility, communication, nutritional intake) with or without pain?		□ No
	d.	Is the request for Botox, Daxxify, or Myobloc?	⊔ Yes	□ No
		If YES, please answer the following questions:	□ Vaa	□Ма
		i. Has the patient tried and had an inadequate response with Xeomin?	⊔ Yes	□ No
		If YES, medical record documentation is required.	□ V	□ Na
		ii. Has the patient tried and had an inadequate response with Dysport?	⊔ Yes	□ No
		If YES, medical record documentation is required.		
		iii. Does the patient have a clinical contraindication or intolerance to BOTH Xeomin		
		AND Dysport?	⊔ Yes	□ No
		If YES, medical record documentation is required.		
8.	Does t	he patient have a diagnosis of chronic anal fissure?	□ Vac	□ No
0.		, please answer the following questions:	163	
		Is the patient 18 years of age or older?	П Vac	□ No
	а. b.	Has the patient tried and had an inadequate response to ONE of the following convention		
	D.	therapies: topical nitrates or topical calcium channel blockers (e.g., diltiazem, nifedipine)		□ No
	C.	Does the patient have documented clinical contraindication or intolerance to ALL topical		
	0.	nitrates and topical calcium channel blockers?		□ No
		Tilliates and topical calcium chamie blockers!	⊔ 165	
9.	Does t	he patient have a diagnosis of esophageal achalasia?	ПУес	□ No
٥.		, please answer the following questions:	103	L 110
		Has the patient failed dilation therapy?	П∨ос	□ No
		Is the patient considered a poor surgical candidate?		□ No
	D.	is the patient considered a poor surgical candidate:	🗀 103	
10	Does to	he patient have a diagnosis of Hirschsprung disease?	□ Yes	□ No
		If YES, did the patient develop obstructive symptoms after a pull-through operation?		□ No
		-,		

continued on page 4; please complete and sign page 6 for prior authorization request

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the priority of their respective owners.



11.	Does th	ne patient have a diagnosis of chronic migraine headache ? ⊻es	□ No
	If YES,	please answer the following questions:	
	a.	Is the patient 18 years of age or older? ☐ Yes	□ No
	b.	Has the patient had ≥ 15 headache days per month for a minimum of 3 months? ☐ Yes	□ No
	C.	Has the patient had ≥ 8 migraine headache days per month for a minimum of 3 months?□ Yes	□ No
		Is the patient using the requested agent for chronic migraine prophylaxis? ☐ Yes	□ No
		Has the patient been evaluated for and ruled out medication overuse headache? ☐ Yes	□ No
	f.	Has the patient had an adequate trial (at least 6 weeks at generally accepted doses with ≥ 80%	
		adherence) and had an inadequate response to any of the following migraine prophylaxis classes	S:
		i. Anticonvulsants (i.e., divalproex, valproate, topiramate)?	□ No
		ii. Beta-blockers (i.e., atenolol, metoprolol, nadolol, propranolol, timolol)? Yes	□ No
		iii. Antidepressants (i.e., amitriptyline, venlafaxine)?□ Yes	□ No
		iv. Calcitonin gene-related peptide (CGRP) receptor antagonists (i.e., fremanezumab,	
		galcanezumab, erenumab, eptinezumab)? Yes	□ No
	g.	Does the patient have a documented clinical contraindication or intolerance to ALL	
	3.	anticonvulsants, beta blockers, antidepressants, and prophylactic CGRP antagonists?□ Yes	□ No
	h.	Will the patient be using the requested medication in combination with a prophylactic CGRP	
		antagonist for migraine prophylaxis?□ Yes	□ No
		If YES, please answer the following questions:	
		i. Has the patient continued to experience 4 or more migraine headache days per	
		month after treatment with at least a 6-month trial (2 injection cycles) with a	
		botulinum toxin agent?□ Yes	□ No
		If YES, please submit medical record documentation.	
		ii. Has the patient continued to experience 4 or more migraine headache days per	
		month after treatment with at least a 3-month trial with a CGRP antagonist?□ Yes	□ No
		If YES, please submit medical record documentation.	
	i.	Is the request for Botox?	□ No
		If YES, please answer the following questions:	
		i. Has the patient tried and had an inadequate response to at least ONE CGRP	
		antagonist for chronic migraine headache prophylaxis (e.g., fremanezumab,	
		galcanezumab, erenumab, or eptinezumab)? Yes	□ No
		If YES, please submit medical record documentation.	
		ii. Does the patient have a documented clinical contraindication or intolerance to ALL	
		CGRP antagonists?□ Yes	□ No
		If YES, please submit medical record documentation.	
		-7.F	
12.	Does th	ne patient have a diagnosis of overactive bladder ? ⊻es	□ No
		please answer the following questions:	
		Is the patient 18 years of age or older?□ Yes	□ No
	b.	Does the patient have symptoms of urge urinary incontinence, urgency, and frequency?□ Yes	□ No
	C.	Has the patient tried and had an inadequate response to ONE anticholinergic agent	
		(e.g., oxybutynin, tolterodine, trospium, solifenacin, etc.)?□ Yes	□ No
	d.	Has the patient tried and had an inadequate response to a beta-3 adrenergic agonist (e.g.,	
		Myrbetriq [mirabegron])?□ Yes	□ No
	e.	Does the patient have a documented clinical contraindication or intolerance to ALL	
		anticholinergic agents AND beta-3 adrenergic agonists? ☐ Yes	□ No
		continued on page 5: please complete and sign page 6 for prior authorization request	

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the priority of their respective owners.



13.	Does tl	he patient have a diagnosis of urinary incontinence with detrusor muscle overactivity		
	associa	ated with neurogenic causes (e.g., spinal cord injury, multiple sclerosis)?	□ Yes	□ No
	If YES,	, please answer the following questions:		
	a.	Is the patient 18 years of age or older?	□ Yes	□ No
	b.	Has the patient tried and had an inadequate response to ONE anticholinergic agent		
		(e.g., oxybutynin, tolterodine, trospium, solifenacin, etc.)?	□ Yes	□ No
	C.	Has the patient tried and had an inadequate response to a beta-3 adrenergic agonist (e	.g.,	
		Myrbetriq [mirabegron])?	□ Yes	□ No
	d.	Does the patient have a documented clinical contraindication or intolerance to ALL		
		anticholinergic agents AND beta-3 adrenergic agonists?	□ Yes	□ No
14.	Does tl	he patient have a diagnosis of neurogenic detrusor overactivity (NDO)?	□ Yes	□ No
		, please answer the following questions:		
	a.	Is the patient 5 years of age or older?	□ Yes	□ No
		Has the patient tried and had an inadequate response to ONE anticholinergic agent		
		(e.g., oxybutynin, solifenacin, etc.)?	□ Yes	□ No
	C.	Does the patient have a clinical contraindication or intolerance to ALL anticholinergic		
		agents?	□ Yes	□ No
15.	Does to	he patient have a diagnosis of sialorrhea (drooling)?	□ Yes	□ No
		, please answer the following questions:		
	a.	Is the patient 18 years of age or older?	□ Yes	□ No
	b.	Is the request for Xeomin?		□ No
		i. If YES, is the patient 2 years of age or older?		□ No
	C.	Is the patient's diagnosis associated with a neurological disorder (e.g., amyotrophic late	ral	
		sclerosis, atypical parkinsonian disorders, cerebral palsy, Parkinson disease, stroke,		
		traumatic brain injury)?		□ No
	d.	Has the patient experienced excessive salivation for ≥3 months?	□ Yes	□ No
	e.	Has the patient tried and had an inadequate response to at least 2 months continuous		
		treatment with at least ONE conventional agent (e.g., anticholinergics, benztropine, oral		
		hyoscyamine, glycopyrrolate)?	□ Yes	□ No
	f.	Does the patient have a clinical contraindication or intolerance to ALL conventional		
		agents?		□ No
	g.	Is the request for Botox, Daxxify, or Myobloc?	□ Yes	□ No
		If YES, please answer the following questions:		
		i. Has the patient tried and had an inadequate response with Xeomin?	⊔ Yes	□ No
		If YES, medical record documentation required.		
		ii. Does the patient have a clinical contraindication or intolerance to Xeomin?	⊔ Yes	□ No
		If YES, medical record documentation required.		
16	Does tl	he patient have a diagnosis of strabismus ?	□ Yes	□ No
. • •		If YES, is the patient 12 years of age or older?		□ No

continued on page 6; please complete and sign page 6 for prior authorization request

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the priority of their respective owners.



	ne patient have a diagnosis of severe primary axillary or palmar hyperhidrosis? Yes please answer the following questions:	□ No
a.	Is the patient 18 years of age or older?	□ No
b.	Does the patient have focal, visible, excessive sweating of at least 6 months duration	
	without apparent cause?	□ No
C.	Does the patient have any of the following characteristics of excessive sweating:	
	i. Bilateral and relatively symmetric sweating?□ Yes	□ No
	ii. Impairment of daily activities?□ Yes	□ No
	iii. Frequency of at least one episode per week? Yes	□ No
	iv. Age of onset is less than 25 years? □ Yes	□ No
	v. Positive family history? ☐ Yes	□ No
	vi. Cessation of focal sweating during sleep? ☐ Yes	□ No
d.	Does the patient have any of the following associated medical conditions:	
	i. Acrocyanosis of the hands?□ Yes	□ No
	ii. History of recurrent skin maceration with bacterial or fungal infections? ☐ Yes	□ No
	iii. History of recurrent secondary infections?	□ No
	iv. History of persistent eczematous dermatitis despite medical treatments with topical	
	dermatologic or systemic anticholinergic agents? ☐ Yes	□ No
e.	Does the patient's hyperhidrosis cause function impairment (e.g., inability to perform activities	
	of daily living and/or manual tasks in a professional setting)? ☐ Yes	□ No
f.	Have potential causes of secondary hyperhidrosis been ruled out (e.g., hyperthyroidism)? ☐ Yes	□ No
a.	Has the patient tried and had an inadequate response with topical medications (e.g.,	
9-	aluminum chloride 20% solution)?□ Yes	□ No
h.	Does the patient have a documented clinical contraindication or intolerance to ALL topical	
	medications?	□ No
If YES,	patient be using the requested medication for another FDA approved indication? Yes	
Medica	al records and references/evidence must be provided in order for this request to be process	ed.
**Non-spec	ific assigned HCPCS codes, must submit requested product NDC	
***Letybo is	FDA approved only for temporary improvement in the appearance of glabellar (frown) lines in adults,	
which is co	nsidered use for cosmetic purposes and therefore use of this product is considered a benefit exclusion.	
Please ce	ertify the following by signing and dating below:	
	at I have been authorized to request prior review and certification for the above requested service	s). I
_	rtify that my patient's medical records accurately reflect the information provided. I understand tha	,
	s NC may request medical records for this patient at any time in order to verify this information. I	-
	derstand that if Blue Cross NC determines this information is not reflected in my patient's medical	
	Blue Cross NC may request a refund of any payments made and/or pursue any other remedies	
available.		
Prescribe	er's Signature (Required): Date:	

For Blue Cross NC members, fax form to 1-888-348-7332

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the priority of their respective owners.



Botulinum Toxin Injection – CONTINUATION

abobotulinumtoxinA (Dysport®), incobotulinumtoxinA (Xeomin®), daxibotulinumtoxinA-lanm (Daxxify®) letibotulinumtoxinA-wlbg (Letybo®), onabotulinumtoxinA (Botox®), rimabotulinumtoxinB (Myobloc®) FOR ADMINISTRATION BY A HEALTHCARE PROFESSIONAL

PRIOR REVIEW/CERTIFICATION REQUEST FOR SERVICES FORM

INCOMPLETE FORMS MAY DELAY PROCESSING
ALL NC PROVIDERS MUST PROVIDE THEIR 5-DIGIT Blue Cross NC PROVIDER ID# BELOW

PATIENT NAME		BLUE CROSS NC	MEMBER ID NUMBER	PATIENT DATE OF BIRT	PATIENT DATE OF BIRTH	
REQUESTING PROVIDER INFORMATION			SERVICING PROVIDER OR FACILITY LOCATION (for services to be performed outside of the physician office)			
Provider Name			Servicing Provider			
Provider #, Tax ID # or NPI			Facility Name			
Street, Bldg., Suite #			Servicing provider or Facility #, or NPI #			
City/State/Zip code			Street, Bldg., Suite #			
Phone #			City/State/Zip code			
Fax #						
PLACE OF SERVICE:	☐ Home Infusion ☐ Offi	ce □ Outpatient h	ospital 🛚 Specialty Pharr	-		
Specialty Pharmacy:			Specialty Pharmacy NP			
HCPCS CODE:			CPT/Other billing code:			
Primary Diagnosis:			ICD-10:			
Drug Requested:						
Strength & Route of Ac	dministration:					
Please select the re	equested medication a	and answer the f	ollowing questions fo	or <u>CONTINUATION</u> cover	age:	
☐ Botox – J05 ☐ Daxxify – J		rt – J0586 oc – J0587	□ ***Letybo – C □ Xeomin – J09	09399, J3490, J3590** 588		
Will the requester	ed agent be used for co	smetic purposes (e.g., glabellar lines, wr	inkles)? Yes	□ No	
and is continuing	2. Was the patient approved for initial coverage for the requested medication through Blue Cross NC and is continuing therapy for one of the initial coverage indications?					
3. Has the patient	had a positive clinical re	sponse to botulin	um toxin therapy?	□ Yes	□ No	
4. Will the patient b	pe receiving botulinum to	oxin more frequer	ntly than every 12 week	xs? Yes	□ No	
continued on page 8; please complete and sign page 8 for prior authorization request						

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the priority of their respective owners.



5.	Does t	he patient have a diagnosis of chronic migraine headache?	□ Yes	□ No
	If YES	, please answer the following questions:		
	a.	Has the patient's migraine headache frequency been reduced by at least 7 days per r		
		compared to pre-treatment frequency?		□ No
	b.	Has the patient's migraine headache duration been reduced by at least 100 hours per	r month	
		compared to pre-treatment duration?		□ No
	C.	Will the patient be using the requested medication in combination with a prophylactic	CGRP	
		antagonist for migraine prophylaxis?		□ No
		If YES, please answer the following questions:		
		 Has the patient continued to experience 4 or more migraine headache days p month after treatment with at least a 6-month trial (2 injection cycles) with a 	er	
		botulinum toxin agent?	□ Yes	□ No
		If YES, please submit medical record documentation.		
		ii. Has the patient continued to experience 4 or more migraine headache days p	er	
		month after treatment with at least a 3-month trial with a CGRP antagonist?		□ No
		If YES, please submit medical record documentation.		
6.	Does t	he patient have a diagnosis of dystonia ?	□ Yes	□ No
		If YES, will the requested medication be used for the treatment of temporomandibular		
		joint (TMJ) disorders?	□ Yes	□ No
		cific assigned HCPCS codes, must submit requested product NDC		
		s FDA approved only for temporary improvement in the appearance of glabellar (frown) line		
wh	ich is co	nsidered use for cosmetic purposes and therefore use of this product is considered a bene	tit exclusion.	
ь	loaso c	ertify the following by signing and dating below:		
		nat I have been authorized to request prior review and certification for the above reques	sted service	(s) I
		ertify that my patient's medical records accurately reflect the information provided. I und		
		ss NC may request medical records for this patient at any time in order to verify this info		. •
		nderstand that if Blue Cross NC determines this information is not reflected in my patier		
		Blue Cross NC may request a refund of any payments made and/or pursue any other r		
	vailable			
P	rescrib	er's Signature (Required): Date:		

For Blue Cross NC members, fax form to 1-888-348-7332

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. Blue Cross NC is an independent licensee of the Blue Cross and Blue Shield Association. All other marks are the priority of their respective owners.